Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE

This study has been completed.
Information provided by:
Korea University Identifier:
First received: November 27, 2009
Last updated: April 5, 2011
Last verified: April 2011
Arteriosclerosis is a dynamic inflammatory disorder. Recently, FDG-PET CT is emerging diagnostic tool of non-invasive technique to detect vulnerable atherosclerotic plaque. And there are arising evidence that sRAGE(soluble Receptor for Advanced glycation End Product) is correlated with metabolic risk. So the investigators will investigate association between sRAGE and FDG-PET uptake in large artery in healthy patient.

sRAGE Level
SUV and TBR Levels in FDG PET

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE

Further study details as provided by Korea University:

Enrollment: 82
Study Start Date: January 2009
Study Completion Date: November 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Type 2 DM, Healthy control
Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
Type 2 DM, Heatlhy control


Ages Eligible for Study:   16 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
type 2 DM diagnoed according to critereia of American Diabetes Asociation.

Inclusion Criteria:

  • Clinical diagnosis od type 2 DM

Exclusion Criteria:

  • Type 1 DM
  • Gestational Diabetes
  • Severe Liver or Renal disease
  • Diagnosis of cancer
  • Trauma
  • Acute infection or inflammatory disease
  • Acute vasculitis or history of vasculitis
  • Pregnant or Lactating women
  • Dyslipidemia(active state)
  • Cardiovascular disease or history of CVD
  • Chronic obstructive pulmonary disease
  • Any patient by judge of investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01021514

Sponsors and Collaborators
Korea University
Principal Investigator: Kyoungmook Choi, MD, PhD Korea University Guro Hospital
  More Information

No publications provided by Korea University

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Korea University Guro Hopital Endocrinology department, Korea University Guro Hospital Identifier: NCT01021514     History of Changes
Other Study ID Numbers: PET(RAGE)
Study First Received: November 27, 2009
Last Updated: April 5, 2011
Health Authority: Korea: Food and Drug Administration

Keywords provided by Korea University:
Type 2 DM processed this record on November 30, 2015